Compare Sinergi Inti Plastindo Tbk. (ESIP) vs Organon Pharma Indonesia Tbk. (SCPI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sinergi Inti Plastindo Tbk. vs Organon Pharma Indonesia Tbk. — how do they compare? Sinergi Inti Plastindo Tbk. trades at Rp122 (market cap 133.19B, 144.65M 24h volume), while Organon Pharma Indonesia Tbk. trades at Rp29,000 (market cap 104.4B). The key difference: Sinergi Inti Plastindo Tbk. is the larger of the two by market cap. Which is the better fit depends on your goals.
| ESIP | SCPI | |
|---|---|---|
Market Cap | 133.19B | 104.4B |
Volume | 144.65M | — |
Lot | 1.45M | — |
Turnover | 18.6B | — |
Average Price | 128.61 | — |
Value | 18.6B | — |
Indicative Equilibrium Price | 122 | — |
Indicative Equilibrium Volume | 17.25K | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sinergi Inti Plastindo Tbk.
PT Sinergi Inti Plastindo Tbk (the”Company”) was established based on the notarial deed No.123 dated October 12, 2001 from Dr. Irawan Soerodjo, S.H., M.Si., Notary in Jakarta. PT Tanindo Omega Pasifik is a ultimate parent entity.
Read more on ESIP →About Organon Pharma Indonesia Tbk.
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Read more on SCPI →
